Phase II trial of lazertinib in patients with epidermal growth factor receptor (EGFR) mutation-positive (M plus ), metastatic non-small cell lung cancer (NSCLC) with asymptomatic or mild symptomatic brain metastases after failure of EGFR tyrosine kinase inhibitor (TKI) (KCSG LU20-15)

  • Hong, Min Hee
  • Choi, Yoon Ji
  • Ahn, Hee Kyung
  • Keam, Bhumsuk
  • Kim, Yu Jung
  • 외 3명
Citations

WEB OF SCIENCE

2
제목
Phase II trial of lazertinib in patients with epidermal growth factor receptor (EGFR) mutation-positive (M plus ), metastatic non-small cell lung cancer (NSCLC) with asymptomatic or mild symptomatic brain metastases after failure of EGFR tyrosine kinase inhibitor (TKI) (KCSG LU20-15)
저자
Hong, Min HeeChoi, Yoon JiAhn, Hee KyungKeam, BhumsukKim, Yu JungKim, Ju WonKim, Hye RyunKang, Jin-Hyoung
발행일
2023-06
유형
Meeting Abstract
저널명
Journal of Clinical Oncology
41
16